Merck, Lundbeck in Sycrest commercialization deal

Merck & Co. Inc. (NYSE:MRK) granted H. Lundbeck A/S (CSE:LUN) exclusive rights outside of the U.S., China and Japan to commercialize Sycrest asenapine. The European Commission approved Sycrest in September to treat moderate to severe manic episodes associated with bipolar I disorder. Lundbeck plans to launch the serotonin (5-HT2) and dopamine D2 receptors antagonist at the beginning of 2011 in the EU. Merck will receive an undisclosed fee and payments for product supply, and is eligible for royalties. ...